Trifluoroacetic acid → HCID 178432926, 화합물
반응식
C(OC([N:8]1[CH2:13][CH2:12][N:11]([C:14]2[CH:19]=[CH:18][C:17]([C:20]3[NH:42][C:23]4=[N:24][CH:25]=[C:26]([Br:41])[C:27]([N:28]5[CH2:33][CH2:32][N:31]([CH2:34][C:35]6[N:36]=[C:37]([CH3:40])[S:38][CH:39]=6)[CH2:30][CH2:29]5)=[C:22]4[N:21]=3)=[CH:16][CH:15]=2)[CH2:10][CH2:9]1)=O)(C)(C)C.C(O)(C(F)(F)F)=O>C(Cl)Cl>[Br:41][C:26]1[C:27]([N:28]2[CH2:29][CH2:30][N:31]([CH2:34][C:35]3[N:36]=[C:37]([CH3:40])[S:38][CH:39]=3)[CH2:32][CH2:33]2)=[C:22]2[N:21]=[C:20]([C:17]3[CH:18]=[CH:19][C:14]([N:11]4[CH2:10][CH2:9][NH:8][CH2:13][CH2:12]4)=[CH:15][CH:16]=3)[NH:42][C:23]2=[N:24][CH:25]=1참가 물질
실험 절차
tert-Butyl-4-(4-(6-bromo-7-(4-((2-methylthiazol-4-yl)methyl)piperazin-1-yl)-3H-imidazo[4,5-b]pyridin-2-yl)phenyl)piperazine-1-carboxylate (0.022 g, 0.033 mmol) was suspended in DCM (2.0 mL) and the mixture cooled in an ice bath. TFA (0.5 mL) was added and the resulting solution was allowed to warm up to room temperature and stirred for 2 h. The mixture was passed through an SCX column (5 g), the filtrate collected and the solvent removed in vacuo to give the title compound as a solid (0.016 g, 86%); 1H-NMR (500 Mz, DMSO-d6): δ 2.61-2.70 (m, 7H), 2.81-2.89 (m, 4H), 3.15-3.22 (m, 4H), 3.60-3.68 (m, 6H), 7.03 (d, J=9.0 Hz, 2H, ArH, C6H4), 7.32 (s, 1H, thiazole 5-H), 8.02 (d, J=9.0 Hz, 2H, ArH, C6H4), 8.17 (s, 1H, imidazo[4,5-b]pyridine 5-H); LC (Method B)-MS (ESI, m/z) 2.23 min—553/555 [(M+H)+, Br isotopic pattern]. ESI-HRMS: Found: 553.1522, calculated for C25H30BrN8S (M+H)+: 553.1498.
후처리
- temperaturethe mixture cooled in an ice bath
- customthe filtrate collected
- customthe solvent removed in vacuo
출처 및 근거
- ORD 기록
- ord-0a174505ef054c12854574756dd0ab5d
- 출처 데이터셋
- uspto-grants-2012_01
- 특허 번호
- US08088761B2
반응 노트
불러오는 중…